Chugai Pharmaceutical Co., Ltd. (Headquarters: Tokyo, Japan, hereafter Chugai) announced that Chugai, Roche and Genentech (collectively, the Companies) have settled globally with Biogen MA Inc. and Bio-Thera Solutions, Ltd. on October 23 in relation to Biogen and Bio-Thera's biosimilar referencing Actemra (generic name: tocilizumab) subject to patent infringement lawsuit in the U.S.

Subsequently, the Companies, Biogen and Bio-Thera will take steps to withdraw the following lawsuit.

Patent infringement lawsuit to be withdrawn

Lawsuit filed at the United States District Court for the District of Massachusetts

Dates of Complaint: July 13, 2023 (local time)

Plaintiff: Chugai, Roche and Genentech

Defendant: Biogen MA Inc. and Bio-Thera Solutions, Ltd.

Patents in suit: Patents related to methods of using tocilizumab in intravenous form, and methods of manufacturing tocilizumab.

The impact on the consolidated financial results for the fiscal year ending December 2023 of Chugai is expected to be negligible.

Contact:

Hideki Sato

Tel: +81-3-3273-0881

Email: pr@chugai-pharm.co.jp

(C) 2023 Electronic News Publishing, source ENP Newswire